Victory Capital Management’s Co-Diagnostics CODX Stock Holding History

Victory Capital Management’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-356	Closed	-$15.8K	–	2534
2023 Q1	$15.8K	Hold	356	–	–	﹤0.01%	2524
2022 Q4	$26.9K	Buy	356 +2	+0.6%	+$187	﹤0.01%	2499
2022 Q3	$34K	Hold	354	–	–	﹤0.01%	2593
2022 Q2	$60K	Sell	354 -24	-6%	-$3.65K	﹤0.01%	2531
2022 Q1	$70K	Buy	378 +53	+16%	+$11K	﹤0.01%	2563
2021 Q4	$87K	Sell	325 -57	-15%	-$15K	﹤0.01%	2594
2021 Q3	$112K	Sell	382 -40	-9%	-$11.7K	﹤0.01%	2603
2021 Q2	$104K	Buy	+422	New	+$108K	﹤0.01%	2593
2020 Q2	–	Sell	-235	Closed	-$54K	–	2673
2020 Q1	$54K	Buy	+235	New	+$40.8K	﹤0.01%	2733
2019 Q4	–	Sell	-55	Closed	-$2K	–	2771
2019 Q3	$2K	Buy	+55	New	+$1.83K	﹤0.01%	3620

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

KOC

Koss-Olinger Consulting Gainesville, Florida $1.19B AUM 15.91% 1-Year Est. Return

Victory Capital Management's CODX Position: Q2 2023 in Review

Victory Capital Management sold out of Co-Diagnostics (CODX) in Q2 2023, closing a stake of 356 shares — an estimated $15.8K sold.

Victory Capital Management first reported a position in CODX in Q3 2019 and held it in 10 quarters. The position peaked at $112K in Q3 2021. 43 funds tracked by Wall St. Rank hold CODX as of Q2 2023.

Victory Capital Management reported no remaining Co-Diagnostics position as of Q2 2023 after selling out during the quarter.
Victory Capital Management sold 356 Co-Diagnostics shares in Q2 2023, an estimated $15.8K.
Victory Capital Management first reported a position in Co-Diagnostics in Q3 2019 and held it in 10 quarters.
Victory Capital Management's Co-Diagnostics position peaked at $112K in Q3 2021.
43 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2023.

Based on Victory Capital Management's 13F filing for Q2 2023, filed 27 Jul 2023.